Ourania Trohatou, Nicholas P. Anagnou and Maria G. Roubelakis Pages 125 - 132 ( 8 )
Recent studies support cell based therapies for several diseases. Human fetal stem cells have received much attention for developing new therapeutic strategies. Recently, our group and others have successfully isolated and expanded karyotypically normal stem cells from an alternative fetal source, the human second trimester amniotic fluid (AF) and performed a systematic phenotypic and molecular analysis. The main characteristics of amniotic fluid stem cells (hAFSCs) are their fetal origin, the high number of isolated cells, their wide differentiation properties and their rapid expansion in vitro. These characteristics render hAFSCs as a very attractive tool for clinical applications based on cell therapy. The use of hAFSC transplantation has been studied in a variety of disease animal models related to bone regeneration, myocardial infarction, acute kidney injury, acute hepatic failure, skin injury, ischemic hind limb or cancer. The major aim of this review is to summarize the advent of hAFSCs capabilities into novel therapeutic modalities and discuss their potential use in future pre-clinical and clinical studies.
Amniotic fluid, animal models, cell transplantation, c-Kit, fetal stem cells, MSCs, stem cell therapy, Regenerative medicine, Anti-inflammatory Response, bone defects, IMMUNOMODULATORY PROPERTIES
Laboratory of Biology, Medical School, University of Athens, Athens 115 27, Greece; Cell and Gene Therapy Laboratory Centre of Basic Research II Biomedical Research Foundation of the Academy of Athens (BRFAA), Athens 115 27, Greece.